Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. More Details
Proven track record with reasonable growth potential and pays a dividend.
Share Price & News
How has Abbott Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ABT is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: ABT's weekly volatility (3%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: ABT exceeded the US Medical Equipment industry which returned 28% over the past year.
Return vs Market: ABT exceeded the US Market which returned 29.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Abbott Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
6 days ago | Simply Wall StWho Has Been Selling Abbott Laboratories (NYSE:ABT) Shares?
2 weeks ago | Simply Wall StI Ran A Stock Scan For Earnings Growth And Abbott Laboratories (NYSE:ABT) Passed With Ease
1 month ago | Simply Wall StNeed To Know: Analysts Are Much More Bullish On Abbott Laboratories (NYSE:ABT)
Is Abbott Laboratories undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: ABT ($119.18) is trading above our estimate of fair value ($87.57)
Significantly Below Fair Value: ABT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ABT is good value based on its PE Ratio (47.5x) compared to the US Medical Equipment industry average (51.7x).
PE vs Market: ABT is poor value based on its PE Ratio (47.5x) compared to the US market (21.4x).
Price to Earnings Growth Ratio
PEG Ratio: ABT is poor value based on its PEG Ratio (2.2x)
Price to Book Ratio
PB vs Industry: ABT is overvalued based on its PB Ratio (6.4x) compared to the US Medical Equipment industry average (5.2x).
How is Abbott Laboratories forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABT's forecast earnings growth (21.3% per year) is above the savings rate (2%).
Earnings vs Market: ABT's earnings (21.3% per year) are forecast to grow faster than the US market (19.6% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: ABT's revenue (6.7% per year) is forecast to grow slower than the US market (10.1% per year).
High Growth Revenue: ABT's revenue (6.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABT's Return on Equity is forecast to be high in 3 years time (23.7%)
How has Abbott Laboratories performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ABT has high quality earnings.
Growing Profit Margin: ABT's current net profit margins (12.9%) are higher than last year (11.5%).
Past Earnings Growth Analysis
Earnings Trend: ABT's earnings have grown significantly by 23.3% per year over the past 5 years.
Accelerating Growth: ABT's earnings growth over the past year (21.4%) is below its 5-year average (23.3% per year).
Earnings vs Industry: ABT earnings growth over the past year (21.4%) exceeded the Medical Equipment industry 9.8%.
Return on Equity
High ROE: ABT's Return on Equity (13.5%) is considered low.
How is Abbott Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: ABT's short term assets ($20.4B) exceed its short term liabilities ($11.9B).
Long Term Liabilities: ABT's short term assets ($20.4B) do not cover its long term liabilities ($27.6B).
Debt to Equity History and Analysis
Debt Level: ABT's debt to equity ratio (56.8%) is considered high.
Reducing Debt: ABT's debt to equity ratio has increased from 42.2% to 56.8% over the past 5 years.
Debt Coverage: ABT's debt is well covered by operating cash flow (42.1%).
Interest Coverage: ABT's interest payments on its debt are well covered by EBIT (11.1x coverage).
What is Abbott Laboratories's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: ABT's dividend (1.51%) is higher than the bottom 25% of dividend payers in the US market (1.31%).
High Dividend: ABT's dividend (1.51%) is low compared to the top 25% of dividend payers in the US market (3.69%).
Stability and Growth of Payments
Stable Dividend: ABT's dividend payments have been volatile in the past 10 years.
Growing Dividend: ABT's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (61%), ABT's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: ABT's dividends in 3 years are forecast to be well covered by earnings (34% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Robert Ford (46 yo)
Mr. Robert B. Ford has been the Chief Executive Officer and Director of Abbott Laboratories since March 31, 2020. He has been President at Abbott Laboratories since October 15, 2018 and served as its Execu...
CEO Compensation Analysis
Compensation vs Market: Robert's total compensation ($USD11.90M) is about average for companies of similar size in the US market ($USD10.53M).
Compensation vs Earnings: Robert's compensation has increased by more than 20% in the past year.
|Executive Chairman of the Board||22.17yrs||US$27.80m||0.18% |
|Executive Vice President of Nutritional Products||6.5yrs||US$6.77m||0.0061% |
|Executive Vice President of Medical Devices||2.17yrs||US$7.48m||0.0034% |
|Executive VP of Finance & CFO||1yr||no data||0.013% |
|Senior Vice President of Core Laboratory Diagnostics & Commercial Operations||1.17yrs||no data||0.0014% |
|Vice President of Investor Relations||no data||no data||no data|
|Executive VP||8.17yrs||US$7.32m||0.0089% |
|VP and Chief Ethics & Compliance Officer||no data||no data||no data|
|Vice President of Public Affairs & Corporate Marketing||no data||no data||no data|
|Senior VP and Chief Marketing & External Affairs Officer||6.25yrs||no data||no data|
|Executive Vice President of Human Resources||1.58yrs||no data||0.0048% |
Experienced Management: ABT's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
|Executive Chairman of the Board||22.17yrs||US$27.80m||0.18% |
|Independent Director||21.17yrs||US$326.91k||no data|
|Independent Director||11.17yrs||US$325.91k||0.00013% |
|Lead Independent Director||no data||US$330.91k||0.0026% |
|Independent Director||4.08yrs||US$300.91k||0.40% |
|Independent Director||14.17yrs||US$331.91k||0.00041% |
|Independent Director||4.17yrs||US$300.91k||0.00020% |
|Independent Director||11.17yrs||US$315.91k||0.00074% |
|Independent Director||9.25yrs||US$306.91k||no data|
|Independent Director||12.42yrs||US$390.23k||no data|
|Independent Director||9.25yrs||US$336.27k||0.00015% |
Experienced Board: ABT's board of directors are seasoned and experienced ( 11.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ABT insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Abbott Laboratories's company bio, employee growth, exchange listings and data sources
- Name: Abbott Laboratories
- Ticker: ABT
- Exchange: NYSE
- Founded: 1888
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$211.131b
- Shares outstanding: 1.77b
- Website: https://www.abbott.com
Number of Employees
- Abbott Laboratories
- 100 Abbott Park Road
- Abbott Park
- North Chicago
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|ABT||NYSE (New York Stock Exchange)||Yes||Common Shares||US||USD||Jan 1968|
|0Q15||LSE (London Stock Exchange)||Yes||Common Shares||GB||USD||Jan 1968|
|ABT||SWX (SIX Swiss Exchange)||Yes||Common Shares||CH||CHF||Jan 1968|
|ABT *||BMV (Bolsa Mexicana de Valores)||Yes||Common Shares||MX||MXN||Jan 1968|
|ABL||XTRA (XETRA Trading Platform)||Yes||Common Shares||DE||EUR||Jan 1968|
|ABL||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Jan 1968|
|ABT||SNSE (Santiago Stock Exchange)||Yes||Common Shares||CL||USD||Jan 1968|
|ABT||BASE (Buenos Aires Stock Exchange)||CEDEAR EACH 4 REP 1||AR||ARS||Sep 2000|
|ABTT34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 4 REP 1 COM||BR||BRL||Aug 2012|
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/03/04 23:42|
|End of Day Share Price||2021/03/04 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.